Clinical impact of second-generation everolimus-eluting stent compared with first-generation drug-eluting stents in diabetes mellitus patients: Insights from a nationwide coronary intervention register

JACC: Cardiovascular Interventions

Volumn 5, Issue 11, 2012, Pages 1141-1149

  Kedhi, Elvin ^a   Gomes, Marc E ^a,b   Lagerqvist, Bo ^c   Smith, J Gustav ^d   Omerovic, Elmir ^b   James, Stefan ^c   Harnek, Jan ^d   Olivecrona, Göran K ^d  

^a Maasstad Hospital Rotterdam   (Netherlands)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

all cause mortality; condensed abstract; diabetes mellitus; everolimus eluting stent; paclitaxel eluting stent; restenosis; SCAAR; sirolimus eluting stent; stent thrombosis

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; EVEROLIMUS ELUTING STENT; FEMALE; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PACLITAXEL ELUTING STENT; PRIORITY JOURNAL; SIROLIMUS ELUTING STENT; STENT THROMBOSIS;

AGED; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; REGISTRIES; RETROSPECTIVE STUDIES; SIROLIMUS; SWEDEN;

EID: 84869460849     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2012.06.020     Document Type: Article

References (31)

1. G.W. Stone, S.G. Ellis, D.A. Cox A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
2. J.W. Moses, M.B. Leon, J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323
3. P. Garg, S.L. Normand, T.S. Silbaugh Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts data analysis center registry Circulation 118 2008 2277 2285
4. M. Sabate, P. Jimenez-Quevedo, D.J. Angiolillo Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (diabetes) trial Circulation 112 2005 2175 2183
5. D. Baumgart, V. Klauss, F. Baer One-year results of the Scorpius study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients J Am Coll Cardiol 50 2007 1627 1634
6. S. Elezi, A. Kastrati, J. Pache Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement J Am Coll Cardiol 32 1998 1866 1873
7. E. Kedhi, K.S. Joesoef, E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
8. G.W. Stone, A. Rizvi, W. Newman Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
9. G.W. Stone, E. Kedhi, D.J. Kereiakes Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus Circulation 124 2011 893 900
10. W.J. Kim, S.W. Lee, S.W. Park Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial Circulation 124 2011 886 892
11. B. Lagerqvist, S.K. James, U. Stenestrand Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden N Engl J Med 356 2007 1009 1019
12. S.K. James, U. Stenestrand, J. Lindbäck Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden N Engl J Med 360 2009 1933 1945
13. B. Lagerqvist, J. Carlsson, O. Fröbert Stent thrombosis in Sweden: A report from the Swedish coronary angiography and angioplasty registry Circ Cardiovasc Interv 2 2009 401 408
14. D.E. Cutlip, S. Windecker, R. Mehran Clinical end points in coronary stent trials: A case for standardized definitions Circulation 115 2007 2344 2351
15. S.W. Lee, S.W. Park, Y.H. Kim A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus J Am Coll Cardiol 52 2008 727 733
16. Grube E. Spirit v diabetic RCT: 9 month angiographic and 1 year clinical follow-up. paper Presented at: EuroPCR, 2010.
17. L. Mauri, W.H. Hsieh, J.M. Massaro, K.K. Ho, R. D'Agostino, D.E. Cutlip Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029
18. G. Sarno, B. Lagerqvist, O. Fröbert Lower risk of stent thrombosis and restenosis with unrestricted use of "new-generation" drug-eluting stents: a report from the nationwide Swedish coronary angiography and angioplasty registry (SCAAR) Eur Heart J 33 2012 606 613
19. E. Kedhi, D.J. Kereiakes Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the spirit ii, spirit iii, spirit iv and compare trials in press SG EuroIntervention 8 2012 599 606
20. D. Kiaei, A.S. Hoffman, T.A. Horbett Tight binding of albumin to glow discharge treated polymers J Biomater Sci Polym Ed 4 1992 35 44
21. M. Joner, G. Nakazawa, A.V. Finn Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 2008 333 342
22. S. Verheye, W. Martinet, M.M. Kockx Selective clearance of macrophages in atherosclerotic plaques by autophagy J Am Coll Cardiol 49 2007 706 715
23. G.G. Biondi-Zoccai, A. Abbate, G. Liuzzo, L.M. Biasucci Atherothrombosis, inflammation, and diabetes J Am Coll Cardiol 41 2003 1071 1077
24. D.J. Kereiakes, D.E. Cutlip, R.J. Applegate Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) J Am Coll Cardiol 56 2010 2084 2089
25. P.W. Serruys, M.C. Morice, A.P. Kappetein Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med 360 2009 961 972
26. G.W. Stone, A. Rizvi, K. Sudhir Randomized comparison of everolimus- and paclitaxel-eluting stents 2-Year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial J Am Coll Cardiol 58 2011 19 25
27. Y. Mitsuuchi, S.W. Johnson, M. Selvakumaran, S.J. Williams, T.C. Hamilton, J.R. Testa The phosphatidylinositol 3-kinase/Akt signal transduction pathway plays a critical role in the expression of p21WAF1/cip1/sdi1 induced by cisplatin and paclitaxel Cancer Res 60 2000 5390 5394
28. P. Rocic Differential phosphoinositide 3-kinase signaling: implications for PTCA? Am J Physiol Heart Circ Physiol 297 2009 H1970 H1971
29. C. Patterson, S. Mapera, H.H. Li Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: role of Akt-dependent signaling Arterioscler Thromb Vasc Biol 26 2006 1473 1480
30. Y. Otsuka, S. Saito, M. Nakamura, H. Shuto, K. Mitsudo Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients Catheter Cardiovasc Interv 78 2011 1078 1085
31. G. Biondi-Zoccai, E. Romagnoli, P. Agostoni Are propensity scores really superior to standard multivariable analysis? Contemp Clin Trials 32 2011 731 740